Dimetacrine: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:Dimetacrine.svg|Dimetacrine chemical structure | |||
File:Dimetacrine-3D-balls.png|Dimetacrine 3D molecular model | |||
</gallery> | |||
Latest revision as of 01:50, 17 February 2025
Dimetacrine (also known as Istonil, Istonyl, Linostil, and Miroistonil) is a tricyclic antidepressant (TCA) that was sold in Europe, particularly in Germany and Switzerland, for the treatment of depression. It is no longer available.
Pharmacology[edit]
Dimetacrine is a tricyclic antidepressant (TCA) and has similar effects to other TCAs. It works by inhibiting the reuptake of certain neurotransmitters, specifically norepinephrine and serotonin, thereby increasing their levels in the brain. This results in mood elevation and relief from symptoms of depression.
Medical Uses[edit]
Dimetacrine was primarily used for the treatment of depression. It was also used in the treatment of anxiety and panic disorders. However, due to the development of newer antidepressants with fewer side effects, it is no longer in use.
Side Effects[edit]
Like other tricyclic antidepressants, Dimetacrine has several side effects. These include dry mouth, constipation, urinary retention, blurred vision, and drowsiness. More serious side effects include cardiac arrhythmias, seizures, and an increased risk of suicide.
History[edit]
Dimetacrine was developed in the mid-20th century and was used in Europe, particularly in Germany and Switzerland. However, it has since been discontinued due to the development of newer, safer antidepressants.
See Also[edit]
-
Dimetacrine chemical structure
-
Dimetacrine 3D molecular model
